http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Hae Rim Kim ),( Hyung Joon Yim ),( Hyun Jung Lee ),( Ei Leen Yoon ),( Sun Jae Lee ),( Sang Jun Suh ),( Rok Son Choung ),( Sung Woo Jung ),( Ja Seol Koo ),( Ji Hoon Kim ),( Jong Eun Yeon ),( Sang Woo 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: There is little clinical information on the effect of telbivudine (LdT) therapy on viral suppression and hepatic function on hepatitis B virus (HBV) patients with cirrhosis. The present retrospective study assessed the antiviral efficacy of LdT therapy for HBV-related cirrhosis. Methods: We consecutively enrolled 35 patients with HBVrelated cirrhosis primarily treated with LdT 600 mg once daily for > 6 months at Korea University College of Medicine between March 2010 and October 2011. The degree of HBV DNA reduction, HBV DNA negativity, ALT normalization, HBeAg seroconversion, and the change of Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) score were analyzed. Results: The baseline mean serum HBV DNA level was 5.21 ± 1.70 log10 IU/ml. The mean reductions in serum HBV DNA levels from baseline to 3 and 6 months were -3.37 ± 1.47, and -3.76 ± 1.67 log10 IU/ml, respectively (all p < 0.05). The proportion of patients with serum HBV DNA negativity (HBV DNA of < 20 IU/ml) and HBeAg seroconversion at 6 months were 51.4% (18/33) and 8.6% (1/32) at 6 months. For all patients, the mean albumin (3.8 vs. 4.0 g/dl) and CTP score (6.0 vs. 5.3) improved after 6 months of LdT treatment than baseline (all p < 0.05). The MELD score numerically decreased without statistical significance (9.5 vs. 8.8, p = 0.104). Although baseline serum HBV DNA and HBeAg status were significant factors in univariate analysis, HBeAg status was only independent factor for predicting HBV DNA negativity at 6 months in multivariate analysis (p = 0.004, OR = 36.4, 95% CI: 3.2-411.2). Conclusions: LdT can effectively inhibit the replication of HBV and improve underlying liver function in patients with cirrhosis resulting from CHB. A more extended prospective study is needed to assess the effect of long-term treatment with this drug.